Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LP-108 and Azacitidine in AML, MDS, and CMML
NCT05641259Phase 1Recruiting
- Sponsor
- Lupeng Pharmaceutical
- Start
- Feb 2023
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of lacutoclax in acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML) (4 arms), sponsored by Lupeng Pharmaceutical. Primary endpoints: Maximum Tolerated Dose up to 42 days, Recommended Phase 2 Dose up to 1.5 years and 8 more. Started Feb 2023; status: recruiting.
02
Drugs
lacutoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT05641259.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05641259.